Market revenue in 2023 | USD 250.9 million |
Market revenue in 2030 | USD 79.1 million |
Growth rate | -15.2% (CAGR from 2023 to 2030) |
Largest segment | Hospitals |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care |
Key market players worldwide | Becton Dickinson & Co, BioMerieux SA, Bio-Rad Laboratories Inc, Abbott Laboratories, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Roche Holding AG, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to molecular diagnostics market will help companies and investors design strategic landscapes.
Hospitals was the largest segment with a revenue share of 47.07% in 2023. Horizon Databook has segmented the Denmark molecular diagnostics market based on hospitals, outpatient facilities, home care covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer is the leading cause of death in Denmark, which has a population of close to 6 million people. More than 45,000 incident instances of cancer were diagnosed in only 2019 alone. women suffered the highest rate of cancer at 328.3 per 100,000. In Denmark, breast cancer affects more women than any other type of cancer, with 4,800 new cases diagnosed every year.
The age range of the majority of breast cancer patients is between 50 and 70 years old. A study conducted in partnership with researchers from the Steno Diabetes Center Copenhagen, Rigshospitalet, and the Department of Nutrition, Exercise, and Sports at the University of Copenhagen found that diabetes risk was enhanced after a cancer diagnosis.
However, cancer survival in Denmark has significantly increased. But for many survivors, complications and persistent effects decrease their quality of life. Several clinical trials are happening in the country. For instance, in May 2022, an article published in Focused Ultrasound Foundation stated that skin cancer clinical trial has begun in Denmark.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Denmark molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account